Terry Jo Brooks-Devlin
Psychiatric/Mental Health · Tonawanda, NYNPI 1831526763
Payments from drug & device makers
Across 945 payments — averaging $185.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$54K
- Neurocrine Biosciences, Inc.$40K
- E.r. Squibb & Sons, L.L.C.$25K
- Teva Pharmaceuticals USA, Inc.$20K
- Otsuka America Pharmaceutical, Inc.$19K
- Axsome Therapeutics, Inc.$7K
- plus $11K from 17 others
What the payments were for
- Consulting fees$25,91815%
- Speaking & faculty fees$114,93365%
- Travel & lodging$13,3718%
- Food & beverage$21,20512%
- Education$3060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 167 | $53,964 |
| Neurocrine Biosciences, Inc. | 140 | $40,324 |
| E.r. Squibb & Sons, L.L.C. | 70 | $24,541 |
| Teva Pharmaceuticals USA, Inc. | 128 | $20,476 |
| Otsuka America Pharmaceutical, Inc. | 124 | $18,610 |
| Axsome Therapeutics, Inc. | 22 | $7,069 |
| AbbVie | 93 | $3,673 |
| Indivior Inc. | 28 | $3,063 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 68 | $1,649 |
| Johnson & Johnson | 45 | $945 |
| Vanda Pharmaceuticals Inc. | 25 | $531 |
| Lundbeck LLC | 18 | $343 |
| Acadia Pharmaceuticals Inc | 1 | $119 |
| Gilead | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 1 | $72 |
| Noven Therapeutics, LLC | 3 | $47 |
| Luye Pharma (USA) Ltd. | 2 | $38 |
| Corium, LLC | 1 | $32 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Biogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$199,523
- INGREZZA$38,125
- UZEDY$18,409
- ABILIFY MAINTENA$17,044
- COBENFY$10,621
- ABILIFY ASIMTUFII$9,947
- Auvelity$6,541
- ARISTADA$5,789
- PERSERIS$2,625
- VRAYLAR$2,475
- ARISTADA INITIO$1,106
- CAPLYTA$376
- Austedo XR$250
- SPRAVATO$224
- NUPLAZID$119
- INVEGA SUSTENNA$110
- INVEGA TRINZA$110
How this compares
$175,733 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $248,806 |
| Austedo XrDeutetrabenazine | 26 | $221,367 |
| AustedoDeutetrabenazine | 17 | $166,747 |
| AristadaAripiprazole Lauroxil | 50 | $164,671 |
| Abilify MaintenaAripiprazole | 39 | $111,198 |
| VraylarCariprazine Hcl | 51 | $73,324 |
| CaplytaLumateperone Tosylate | 29 | $49,975 |
| RexultiBrexpiprazole | 25 | $36,621 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $35,927 |
| UzedyRisperidone | 11 | $28,049 |
| TrintellixVortioxetine Hydrobromide | 37 | $20,917 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,136 |
| Aripiprazole | 105 | $4,435 |
| Ziprasidone Hcl | 17 | $3,805 |
| Prazosin Hcl | 131 | $3,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $20,476 | $416,16254 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $40,324 | $248,80631 claims |
| Alkermes, Inc.Aristada, Lybalvi | $53,964 | $200,59872 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $18,610 | $147,81864 claims |
| AbbVieVraylar | $3,673 | $73,32451 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,649 | $49,97529 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $20,91737 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $29 | $18,13612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Tonawanda
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.